Entrada Therapeutics Inc. Revenue 2023–2025
Entrada Therapeutics Inc. annual/quarterly revenue history and growth rate from 2023 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Entrada Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 875000, a 95.74% decrease year-over-year.
- Entrada Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 25.0 M, a 88.49% decrease year-over-year.
- Entrada Therapeutics Inc. annual revenue for 2025 was 25.4 M, a 87.94% decrease from 2024.
- Entrada Therapeutics Inc. annual revenue for 2024 was 210.8 M, a 63.38% increase from 2023.
- Entrada Therapeutics Inc. annual revenue for 2023 was 129.0 M.
Entrada Therapeutics Inc. (TRDA) — Frequently Asked Questions
Entrada Therapeutics Inc. (TRDA) is a publicly traded US company. It has a market capitalization of $247M. In fiscal 2025 it reported revenue of $25M and net income of -$144M. Explore TRDA's stock price, financial statements, earnings history, margins and key ratios below.
What is Entrada Therapeutics Inc.'s market cap?
Entrada Therapeutics Inc. (TRDA) has a market capitalization of $247M.
What is the TRDA stock price?
TRDA trades at $5.97 (-6.28% on the day).
How much revenue does Entrada Therapeutics Inc. make?
Entrada Therapeutics Inc. reported revenue of $25M in fiscal 2025.
Is TRDA profitable?
In fiscal 2025, Entrada Therapeutics Inc. reported net income of -$144M.